|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:activities
|
norepinephrine-dopamine reuptake inhibitor
|
|
gptkbp:approves
|
gptkb:1985
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Zyban
gptkb:Aplenzin
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:clinical_trial
|
weight management
anxiety disorders
bipolar disorder
depression treatment
smoking cessation
|
|
gptkbp:contraindication
|
eating disorders
seizure disorder
|
|
gptkbp:discovered_by
|
gptkb:Eli_Lilly
|
|
gptkbp:dosage_form
|
100 mg
150 mg
300 mg
|
|
gptkbp:duration
|
varies
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:tablet
extended-release tablet
sustained-release tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Wellbutrin
|
|
gptkbp:ingredients
|
C13 H18 Cl N O2
|
|
gptkbp:interacts_with
|
gptkb:beer
MAO inhibitors
other antidepressants
|
|
gptkbp:is_atype_of
|
N06 A X12
|
|
gptkbp:is_available_on
|
prescription medication
|
|
gptkbp:is_used_for
|
gptkb:historical_event
anxiety
ADHD
|
|
gptkbp:lifespan
|
21 hours
|
|
gptkbp:marketed_as
|
gptkb:Wellbutrin_SR
gptkb:Wellbutrin_XL
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:previous_name
|
gptkb:bupropion
|
|
gptkbp:side_effect
|
dizziness
nausea
weight loss
insomnia
dry mouth
|
|
gptkbp:suitable_for
|
pregnant women
children under 18
people with a history of seizures
|
|
gptkbp:symptoms
|
possible
|
|
gptkbp:treatment
|
varies by individual
|
|
gptkbp:type_of
|
34841-39-9
|
|
gptkbp:type_of_care
|
important
|